Physician profile
Whitney E Shoemaker
NPI 1750328514
$5,469.42
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $704 · 2021: $1,926 · 2022: $853 · 2023: $661 · 2024: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,430.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,220.73 | 2020-2023 | Axonics |
| Astellas Pharma US INC | $653.40 | 2019-2024 | Veozah, Myrbetriq |
| Novo Nordisk INC | $513.27 | 2019-2024 | Wegovy |
| Hologic Sales and Service, LLC | $503.76 | 2019-2024 | Myosure Tissue Removal Device, Aptima, Thinprep 2000 Processor |
| Abbvie INC. | $422.28 | 2019-2024 | Botox |
| Amgen INC. | $416.86 | 2019-2024 | Repatha |
| Caldera Medical, INC | $326.55 | 2020-2021 | |
| Allergan, INC. | $278.06 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $149.76 | 2021-2023 | |
| Exeltis, USA INC. | $112.91 | 2019-2023 | Slynd |
| Lilly USA, LLC | $96.67 | 2024 | Mounjaro |
| Therapeuticsmd, INC. | $86.58 | 2020-2022 | |
| Minerva Surgical, INC | $82.54 | 2019-2022 | |
| Lupin INC. | $70.82 | 2019-2020 | |
| Coloplast Corp | $69.57 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $50.65 | 2020-2021 | |
| Boston Scientific Corporation | $48.48 | 2019-2021 | |
| Daiichi Sankyo INC. | $45.63 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $39.48 | 2020 | |
| Meditrina | $39.40 | 2020-2022 | |
| Millicent US INC | $39.19 | 2023-2024 | Intrarosa, Femring |
| Evofem Biosciences, INC. | $31.30 | 2021-2022 | |
| Myovant Sciences INC. | $30.22 | 2021-2022 | |
| Avion Pharmaceuticals | $25.89 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $19.65 | 2019 | |
| Becton, Dickinson and Company | $18.42 | 2023 | Bd Onclarity |
| Aspira Women'S Health INC | $18.38 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.91 | 2020 | |
| Amag Pharmaceuticals, INC. | $15.44 | 2019 | |
| Medtronic, INC. | $13.80 | 2021 | |
| Dysis Medical, INC. | $12.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Shoemaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.